Archive

Archive for June 21st, 2009

Fuad El-Hibri remembers Ibrahim Y. El-Hibri

June 21st, 2009 admin No comments

Ibrahim was the beloved husband of Liane El-Hibri and father of Fuad El-Hibri and Samir El-Hibri and Yasmine Gibellini.  He had six grandchildren, whom he cherished and adored.  He is also survived by his father, Yahia El-Hibri, two sisters, Dr. Azizah Al-Hibri and Dr. Huda Zoghbi, and two brothers, Dr. Jamal El-Hibri and Dr. Tayeb El-Hibri.

Businessman and philanthropist Ibrahim Y. El-Hibri passed away on August 23, 2007.

Born in Beirut, Lebanon, on September 8, 1936, Ibrahim became a successful telecommunications engineer and entrepreneur who built nationwide telecommunication networks in many countries around the world.  In his later years, he focused on life sciences, supporting the development of life saving vaccines.  Among numerous other accomplishments, Ibrahim received official decorations for extraordinary deeds from the Governments of Germany, Lebanon and Venezuela.

As an unwavering philanthropist, Ibrahim was tireless in his support of children and orphans in Lebanon and other parts of the world.  His generosity, kindness, and commitment to these endeavors in the spirit of Islam will be sorely missed.  The El-Hibri Charitable Foundation will carry on his legacy.

The traditional 4-day memorial service was held for him on November 18, 2007, during which his son, Fuad, delivered remarks about his father’s life and accomplishments.

Mr. El-Hibri was the very first subscriber to Al-Hewar Magazine back in 1989.  We will remain forever grateful to Mr. El-Hibri for his ceaseless encouragement for our efforts over the years.

God bless his soul.

Fuad El-Hibri final remarks Ibrahim El-Hibri memorial

November 18, 2007

Ibrahim El-Hibri MEMORIAL

Fuad El-Hibri REMARKS

Thank you so much, ladies and gentlemen, for attending my father’s memorial tonight.  In the Middle East, it is customary to grieve for 40 days after the passing of a loved one.  This is why we waited until now to hold the memorial for him. — This is the official reason — the practical reason is that we wanted to host the event at the El-Hibri Charitable Foundation here in this building — and as you can see, the building has been undergoing major renovation until Friday – a very close call.

Before we start, I would like to thank Rusty Squire for supervising the recent renovation of this building – also, Bob Smith, President and Zen Hunter-Ishikawa, Director of the Foundation, for managing the logistics for this event.  Last but not least, I would like to thank my sister, Yasmine, for helping organize and coordinate this important event.

Tonight, we want to remember my father – we want to celebrate his life – we want to share stories.  It has been almost three months, and we still cannot believe that he has moved on!

Tonight, we will have 7 speakers, friends and family members who have asked to make a few remarks in his honor.  Since I was given the pleasure to welcome you all, I will start.

As many of you know, my father was an extraordinary man – a successful businessman, a devout Moslem, a generous philanthropist, a loving husband, a family patriarch.  His generosity spanned a wide spectrum – from financial giving – to love, affection, and an unwavering commitment to those he loved.

First, let me tell you about – My father as a successful businessman

He studied electrical engineering in Hanover, Germany as a young man.  After 5 years of education, he joined Philips – at the time, one of the premier telecommunications companies in the world – to pursue a career which turned out to be a monumental success.  Among his remarkable accomplishments:

1. He helped the Saudi Arabian government to build its first nationwide telecommunication network – the largest telecom contract ever signed in the world at that time.
2. He constructed the longest microwave link connecting the Sudan and Saudi Arabia – a deed commemorated by a stamp that was issued in Italy for this project.
3. He built the first GSM mobile network in Russia, now with over 20 million subscribers in the Moscow region alone.

There are many more…  My father had an air about him that mesmerized people – he was bright, formal, respectful, elegant, and extremely charismatic.

He demanded the impossible and actually often succeeded in achieving the impossible.  I witnessed meetings during which he had the power of conviction that left people reeling for many days.

His ability to persuade and persevere – was uncanny.  He was decorated for extraordinary public service by the government of Germany, Lebanon, and Venezuela.

And now – My father as devout Moslem

My father gained his strength and energy from his belief in God.  This spiritual foundation enabled him to consistently project a positive outlook on life and people – it was truly infectious.  I have never seen him depressed or anything short of jovial and excited to be around his family and friends.  My father believed in interfaith and the commonality of the three monolithic religions – stressing similarities rather than differences.

Bringing believers in one God together was one of his primary goals.  He wanted to portray Islam in a manner that it deserves – in an objective, unbiased, and constructive way.  As a believer, he put words into action – he purchased this building and started The El-Hibri Charitable Foundation with one of its main missions focused on interfaith education and integration.

And now – My father as a generous philanthropist

In addition to the Foundation, my father was a great supporter of orphans.  He believed that no child should be left behind – well before our politicians came up with this slogan!

To provide shelter and a home, he constructed and dedicated a building in Beirut that can house, feed, and educate over 200 orphans.

Also, many friends and family members were able to earn advanced degrees from some of the best universities in the US and around the world because of his financial support.  There are many other philanthropic deeds – too many to list them all.  His generosity was endless – and his gifts kept on giving.  His hospitality was boundless, warm, – and emanated deep from his heart.

And now – My father as a loving husband

At the tender age of 22, my father married the love of his life.  It was love at first sight – or should I say bite!  My father used to love giving us ever so gentle bites on our forearms when we were younger.  The ultimate testimony of his steadfast love for my mother is 50 years of marriage.  Always concerned for her well being, my father showered her with gifts, protected her from the less pleasant realities of this world, and allowed my mom to focus her undivided attention to our family.  We children are the true beneficiaries of our father’s love and care for our wonderful mother.

And finally – My father as a family patriarch

As the head of our family, he was an exemplary father, a doting grandfather, a caring eldest brother. Very disciplined and principled in his way, he taught us well and always led by example.

He would light up – with a grin from ear to ear – when family would come to visit him, especially his grandchildren, which he adored so much.

When spending time with his family, he relaxed and radiated exuberance – these moments were clearly the climax of his life.  And – he had a great sense of humor.  My father, who spoke 7 languages fluently, was able to mimic characters from movies and real life – flawlessly.  We would all burst out in laughter.  One of his greatest pleasures, however, was watching Faiza, his then youngest granddaughter, perform.  He was the first to recognize Faiza’s wonderful talent and skill in performing arts and theater.  He would ask her to act over and over again – what joy he derived!  His legacy continues with her.  We miss him sorely.

There is so much more to share and many legacies left behind – but I must allow others to speak.  Thank you, ladies and gentlemen – now I would like to ask Farouk Jabre, a dear friend of my father’s, to come to the podium.

El-Hibri dedication

Businessman and philanthropist Ibrahim Y. El-Hibri passed away on August 23, 2007.

Born in Beirut, Lebanon, on September 8, 1936, Ibrahim became a successful telecommunications engineer and entrepreneur who built nationwide telecommunication networks in many countries around the world.  In his later years, he focused on life sciences, supporting the development of life saving vaccines.  Among numerous other accomplishments, Ibrahim received official decorations for extraordinary deeds from the Governments of Germany, Lebanon and Venezuela.

As an unwavering philanthropist, Ibrahim was tireless in his support of children and orphans in Lebanon and other parts of the world.  His generosity, kindness, and commitment to these endeavors in the spirit of Islam will be sorely missed.  The El-Hibri Charitable Foundation will carry on his legacy.

Ibrahim was the beloved husband of Liane El-Hibri and father of Fuad and Samir El-Hibri and Yasmine Gibellini.  He had six grandchildren, whom he cherished and adored.  He is also survived by his father, Yahia El-Hibri, two sisters, Dr. Azizah Al-Hibri and Dr. Huda Zoghbi, and two brothers, Dr. Jamal El-Hibri and Dr. Tayeb El-Hibri.

The traditional 4-day memorial service was held for him on November 18, 2007, during which his son, Fuad, delivered remarks about his father’s life and accomplishments.

Mr. El-Hibri was the very first subscriber to Al-Hewar Magazine back in 1989.  We will remain forever grateful to Mr. El-Hibri for his ceaseless encouragement for our efforts over the years.

God bless his soul.

Fuad El-Hibri Remembers Ibrahim El-Hibri

Jun 14
Comments

Fuad El-Hibri Remembers Ibrahim El-Hibri

Inna Lillahi Wa Inna Ilayhi Raji’un
Verily we belong to God, and to God we return

In Memoriam: Mr. Ibrahim El-Hibri

Karamah is deeply saddened to announce the passing of our dear friend and extraordinary leader, Mr. Ibrahim El-Hibri, who passed away on Thursday, August 23, 2007, in Paris, France.  Mr. El-Hibri was born in Beirut, Lebanon, on September 8, 1936.

A devout Muslim, he was the beloved husband of Liane El-Hibri and father of Fuad and Samir El-Hibri and Yasmine Gibellini.  He leaves behind six grandchildren, whom he cherished and adored.  He is also survived by his father, Yahia El-Hibri, two sisters, Dr. Azizah Al-Hibri and Dr. Huda Zoghbi, and two brothers, Dr. Jamal El-Hibri and Dr. Tayeb El-Hibri.

Mr. El-Hibri will be remembered as a successful telecommunications engineer and entrepreneur who built nationwide telecommunication networks in several countries. In his later years, he focused on life sciences, supporting the development of life saving vaccines.  Among numerous other accomplishments, Mr. El- Hibri received official decorations for extraordinary deeds from the Governments of Germany, Lebanon and Venezuela.

As an unwavering philanthropist, Mr. El-Hibri was tireless in his support of women, children and orphans in Lebanon and other parts of the world.  He was also an enthusiastic and major supporter of Karamah since its early years.  His generosity, kindness, and commitment to these endeavors in the spirit of Islam will be sorely missed.  He has been described as a human being who exemplified humanity in its truest form; he depicted generosity, kindness, grace, and good will in every moment of his life.

Karamah will forever appreciate and remember Mr. El-Hibri for his unwavering support, devotion, inspiration, guidance, and instrumental role in developing the organization to the level it has achieved today.

A memorial service and funeral prayers (janazah) will be held for Mr. El-Hibri on Thursday, August 30, 2007 at 10:00 a.m. at The Islamic Center, 2551 Massachusetts Avenue, NW, Washington, DC.

In lieu of flowers, memorial contributions may be made to any of the following non-profit, tax-exempt organizations:

El-Hibri Charitable Foundation (for the Dar-Al-Aytam Orphanage in Lebanon)
1420 16th Street, NW
Washington, DC  20036

Karamah (Muslim Women for Human Rights)
T.C. Williams School of Law
University of Richmond
Richmond, VA  23173

Child Help
c/o Heather Corsini
11622 Highland Farm Road
Potomac, Maryland 20854

Reblog this post [with Zemanta]
Categories: Advisory Board, Atlanta Business Chronicle, BioThrax, Earnings Report, El-Hibri Foundation, Emergent BioSolutions, Entrepreneur of the Year, Ernst & Young, Fuad El-Hibri, Muslim, Profits and Losses, Shareholders, Tag Cloud, Washington DC, Washington Gala, Yale Health Care, Yale School of Management, Yale University Tags: , , , , , , ,

Fuad El-Hibri Yale Health Care Advisory Board

June 21st, 2009 admin No comments

Mr. Fuad El-Hibri has served as chief executive officer and chairman of the board of directors of Emergent Biosolutions Inc., since June 2004 and as president from March 2006 to April 2007. Mr. El-Hibri served as chief executive officer and chairman of the board of directors of BioPort Corporation from May 1998 until June 2004, when, as a result of corporate reorganization, BioPort became a wholly owned subsidiary of Emergent. Mr. El-Hibri served as chairman of Digicel Holdings, Ltd., a privately held telecommunications firm, from August 2000 to October 2006. Fuad El-Hibri Yale Health Care Advisory Board

Fuad El-Hibri, MBA
Chief Executive Officer and Chairman of the Board of Directors
Emergent Biosolutions, Inc.
Yale School of Management

Mr. El-Hibri has served as chairman of East West Resources Corporation, a venture capital and financial consulting firm, since June 1990. He served as president of East West Resources from September 1990 to January 2004. Mr. El-Hibri is a member of the board of trustees of American University and a member of the board of directors of the International Biomedical Research Alliance, an academic joint venture among the NIH, Oxford University and Cambridge University. He also serves as chairman and treasurer of El-Hibri Charitable Foundation. Mr. El-Hibri received a master’s degree in public and private management from Yale University and a B.A. in economics from Stanford University.
Reblog this post [with Zemanta]
Categories: BioThrax, Earnings Report, El-Hibri Foundation, El-Hibri Fuad, El-Hibri Peace Education, El-Hibri Peace Education Prize, Emergent BioSolutions, Entrepreneur of the Year, Ernst & Young, FDA, Food and Drug Administration, Fuad El-Hibri, Fuad Elhibri, Hepatitis B Vaccine, Hepatitis Vaccine, Islam, Shareholders, Uncategorized, W. James Jackson, Washington DC, Washington Gala, Yale Health Care, Yale School of Management, Yale University Tags: , , , , , , ,

Fuad El-Hibri EBS IPO and BioThrax

June 21st, 2009 admin No comments

“When you have two parties you can maybe exercise control over one party, which is ourselves. Our relationship with HHS continues to be strong, and we’re excited about this opportunity,” said Fuad El-Hibri, chief executive officer, in a conference call with analysts. “These are half-billion-dollar types of contracts. They just take time to negotiate.”

Delayed orders of its anthrax product drastically cut into Emergent BioSolutions Inc.’s fourth-quarter revenue and profits.

The Rockville biotech earned nearly $35.8 million in revenue in the fourth quarter last year, a 60 percent drop from the $89.6 million it pulled in during the same period of 2007. That also resulted in a nearly 95 percent plunge in fourth-quarter profits, from $27.7 million to nearly $1.5 million.

The company said it had expected to ship three additional lots of its BioThrax anthrax vaccine to the U.S. Department of Health and Human Services during the fourth quarter — representing $12 million worth of product sales — but that delivery was delayed.

“Such an event is further evidence that our revenues fluctuate quarter to quarter based on the timing of deliveries of BioThrax to HHS,” said Don Elsey, chief financial officer, in a statement.

Despite that drop, Emergent’s revenue for the full year in 2008 dipped only 2 percent, from $182.9 million to $178.5 million, and profit fell 10 percent, from $22.9 million to $20.7 million. Nearly all of the company’s product sales came from BioThrax, and Emergent said it saw a 16 percent drop in BioThrax doses delivered to HHS. That was offset, though, by an 18 percent rise in Emergent’s BioThrax dose price.

The company earns most of its money from HHS contracts. While Emergent still has two contracts outstanding, worth a total $853 million, to deliver more than 33 million doses to HHS, the larger of those two contracts, worth $448 million, will be completed in the third quarter of this year.

Emergent is awaiting an HHS decision on its bid last year to sell 25 million doses of a separate anthrax vaccine to the agency — a negotiation process that has been delayed by a protest from one of the other bidders on the HHS request for proposals, Emergent officials said.

Emergent thinks its revenue this year will grow by 25 to 35 percent and lie between $225 million and $240 million. It also expects profits to exceed $20 million this year.

Emergent had plans to expand its manufacturing space into Frederick, Md., but those plans have been put on hold as it concentrates its work at a current plant in Lansing, Mich. Emergent officials have been wary of giving any timelines for further manufacturing expansions but did say nothing would occur before the end of next year.

“We would be using existing manufacturing process, existing scale, existing equipment,” El-Hibri said. “We have plenty of space.”

By the end of last year, the company had $91.5 million in cash and equivalents.

Emergent’s share price (NYSE: EBS) dropped $1.08, or a little more than 6 percent, in trading after closing bell Thursday, when the company released its earnings.

Fuad El-Hibri and EBS Initial Public Offering

A Gaithersburg drug company that makes most of its money selling the only federally approved vaccine against anthrax is in the final stages of preparing an initial public offering to raise up to $92 million.

Late last month, Emergent Biosolutions Inc. set the range of its offering at $14 to $16 a share. The company said it intends to use the money on its manufacturing facilities in Frederick and Michigan and to fund development of several products, according to documents filed with the Securities and Exchange Commission.

The company is tightly controlled by Fuad El-Hibri, its chairman and chief executive. El-Hibri, who lives in Potomac, has an extensive background in the telecommunications industry. He and his father have also had significant involvement with a British provider of anthrax vaccines. El-Hibri, who became a U.S. citizen in 1999, was born in Germany and grew up around Europe and the Middle East before attending Stanford and Yale universities.

El-Hibri controls 99.5 percent of the Emergent’s outstanding stock. After going public, he will control 81.4 percent. In SEC documents, the company said El-Hibri “will continue to have substantial control over us after this offering, including through his ability to control the election of the members of our board of directors, and could delay or prevent a change of control.”

Biotech analysts said Emergent could have a tough time with its initial public offering. Just two biotech companies — Osiris Therapeutics, a Baltimore biotechnology firm working on stem-cell therapies, is one — went public in the third quarter, and the market for IPOs in general has been spotty.

According to Thomson Financial, more companies have withdrawn IPOs this year than in any of the previous five years, indicating investors are skeptical of new company stock offerings despite the generally strong market for stocks. And venture capital-backed IPOs, traditionally the most prolific source of new company issues, fell significantly in the third quarter.

Companies that have managed to go public are in a broad range of industries, and those that have had the most success are in tried-and-true money-making or technologically hot industries. For example, locally, government contracting giant SAIC Inc. is up 33 percent since its Oct. 12 IPO. And Osiris Therapeutics is up 89 percent since its August IPO.

Emergent Biosolutions’ effort to finish its IPO comes as federal health officials deal with a troubled $877.5 million contract for another anthrax vaccine, made by VaxGen Inc. VaxGen is supposed to provide 75 million doses for the national stockpile, but the Food and Drug Administration recently halted human testing of the California company’s vaccine because of concerns about its potency, throwing the entire contract into doubt.

VaxGen’s contract was awarded under the Project Bioshield initiative, which seeks to develop modern vaccines and drugs for chemical, biological, radiological or nuclear attacks. VaxGen’s proposed anthrax vaccine, if successful, would require fewer doses over a shorter period of time to produce immunity than the older version made by Emergent.

Emergent has been urging Congress and federal health officials to buy more of its anthrax vaccine, called BioThrax, for the stockpile. The efforts are being aided by Louis W. Sullivan, who was health and human services secretary from 1989 to 1993, and Jerome M. Hauer, a former senior HHS official who oversaw public health emergency preparedness. Both men are on Emergent’s board.

So far, the government has purchased 10 million doses.

In its SEC filings, Emergent said the government’s efforts to stockpile a newer version “would limit, possibly significantly, the market for BioThrax.” The company said it is in the early stages of developing a next-generation anthrax vaccine and products for other diseases and bioterrorism agents.

Emergent officials could not comment because the company is in a quiet period before its offering.

While the $5.6 billion Project Bioshield program is potentially the most lucrative outlet for BioThrax, Emergent also sells the vaccine to the Defense Department. Since 1998, the Defense Department has vaccinated 1.5 million people with more than 5.7 million doses, according to SEC documents. It is providing 1.5 million doses to the military through September 2007.

BioThrax has been controversial in the military. Some soldiers have complained of significant side effects and have refused to use the vaccine, leading to a court battle that temporarily stopped mandatory vaccinations. The government recently resumed mandatory vaccinations with BioThrax after the FDA said the vaccine was safe and effective.

John T. McCamant, editor of the Medical Technology Stock Letter, said Emergent’s IPO could be particularly difficult because the only customer for bioterrorism products is the government.

“That’s a tall trick because the money will come in lumps at best,” he said.

Staff writer Terence O’Hara contributed to this report.

Posted in El-Hibri Fuad, Emergent BioSolutions, Emergent BioSolutions Inc, Fuad El-Hibri, Initial Public Offering
Tags: , , , , , , ,

Reblog this post [with Zemanta]
Categories: BioThrax, Emergent BioSolutions, Fuad El-Hibri, Initial Public Offering Tags: , , , , , , ,

Fuad El-Hibri at Washington Gala

June 21st, 2009 admin No comments

The Keynote address was given by H.E. Ambassador Antoine Chedid. Distinguished Community Service and Achievement Awards were given to two very deserving recipients: Mr. Fuad El-Hibri, Chairman and CEO of Emergent BioSolutions, and the Partnership for Lebanon, established in September 2006 by US business leaders to assist the reconstruction efforts and to help the people of Lebanon find the path to long-term stability and economic growth. The Partnership’s leaders include the CEOs of Microsoft, Cisco Systems, Intel Corporation, Ghafari Inc. and Occidental Petroleum. Fuad El-Hibri at Washington DC Gala

The Gala brought together some 430 Arab and Lebanese-Americans, as well as former and current U.S. Administration officials, Arab ambassadors and diplomats, and Lebanese-American leaders from around the USA, all united by a common will of promoting peace and stability in Lebanon.

H.E. Nayla Moawad, Founder and Honorary President of the Foundation, former First Lady of Lebanon, and current Minister of Social Affairs hosted this special occasion. Some of the honored guests included Minister Sami Haddad and Minister Jihad Azour. Former World Bank President Paul Wolfowitz was also in attendance.

The Keynote address was given by H.E. Ambassador Antoine Chedid. Distinguished Community Service and Achievement Awards were given to two very deserving recipients: Mr. Fuad El-Hibri, Chairman and CEO of Emergent BioSolutions, and the Partnership for Lebanon, established in September 2006 by US business leaders to assist the reconstruction efforts and to help the people of Lebanon find the path to long-term stability and economic growth. The Partnership’s leaders include the CEOs of Microsoft, Cisco Systems, Intel Corporation, Ghafari Inc. and Occidental Petroleum.

The evening also featured a fashion show by the renowned Lebanese designer Jean Fares, who is known for combining beauty and fashion. His designer collection is designed with original concepts and an impeccable finish.

This year’s event will support the many educational programs that RMF is undertaking in Lebanon, thereby giving its youth a better educational environment and a more promising future.


H.E. Mrs Nayla Moawad


Minister Jihad Azour, Mr. Abdo Sabban
and Ambassador Vincent Battle


Mrs. A. Chedid, Ambassador A. Chedid, Mrs. Moawad, Mr. Paul Wolfowitz and Mr. Michel Moawad


Mr. Michel Moawad, MP Jawad Boulos


Mrs. Moawad presenting award to Mr. Fuad El-Hibri


From the fashion show


Mrs Moawad presenting award to Mr. Jean Fares

Reblog this post [with Zemanta]
Categories: El-Hibri Fuad, Fuad El-Hibri, Washington DC, Washington Gala Tags: , , , , , , ,

Fuad El-Hibri Profits and Losses

June 21st, 2009 admin No comments

“When you have two parties you can maybe exercise control over one party, which is ourselves. Our relationship with HHS continues to be strong, and we’re excited about this opportunity,” said Fuad El-Hibri, chief executive officer, in a conference call with analysts. “These are half-billion-dollar types of contracts. They just take time to negotiate.”

Fuad El-Hibri and Emergent BioSolutions Inc. Profits and Losses

Delayed orders of its anthrax product drastically cut into Emergent BioSolutions Inc.’s fourth-quarter revenue and profits.

The Rockville biotech earned nearly $35.8 million in revenue in the fourth quarter last year, a 60 percent drop from the $89.6 million it pulled in during the same period of 2007. That also resulted in a nearly 95 percent plunge in fourth-quarter profits, from $27.7 million to nearly $1.5 million.

The company said it had expected to ship three additional lots of its BioThrax anthrax vaccine to the U.S. Department of Health and Human Services during the fourth quarter — representing $12 million worth of product sales — but that delivery was delayed.

“Such an event is further evidence that our revenues fluctuate quarter to quarter based on the timing of deliveries of BioThrax to HHS,” said Don Elsey, chief financial officer, in a statement.

Despite that drop, Emergent’s revenue for the full year in 2008 dipped only 2 percent, from $182.9 million to $178.5 million, and profit fell 10 percent, from $22.9 million to $20.7 million. Nearly all of the company’s product sales came from BioThrax, and Emergent said it saw a 16 percent drop in BioThrax doses delivered to HHS. That was offset, though, by an 18 percent rise in Emergent’s BioThrax dose price.

The company earns most of its money from HHS contracts. While Emergent still has two contracts outstanding, worth a total $853 million, to deliver more than 33 million doses to HHS, the larger of those two contracts, worth $448 million, will be completed in the third quarter of this year.

Emergent is awaiting an HHS decision on its bid last year to sell 25 million doses of a separate anthrax vaccine to the agency — a negotiation process that has been delayed by a protest from one of the other bidders on the HHS request for proposals, Emergent officials said.

Emergent thinks its revenue this year will grow by 25 to 35 percent and lie between $225 million and $240 million. It also expects profits to exceed $20 million this year.

Emergent had plans to expand its manufacturing space into Frederick, Md., but those plans have been put on hold as it concentrates its work at a current plant in Lansing, Mich. Emergent officials have been wary of giving any timelines for further manufacturing expansions but did say nothing would occur before the end of next year.

“We would be using existing manufacturing process, existing scale, existing equipment,” El-Hibri said. “We have plenty of space.”

By the end of last year, the company had $91.5 million in cash and equivalents.

Emergent’s share price (NYSE: EBS) dropped $1.08, or a little more than 6 percent, in trading after closing bell Thursday, when the company released its earnings.

Reblog this post [with Zemanta]
Categories: Emergent BioSolutions, Fuad El-Hibri, Profits and Losses Tags: , , , , , , ,

the American University Board of Trustee Fuad El-Hibri

June 21st, 2009 admin No comments

Fuad El-Hibri, President, East West Resources Corp., Rockville, MD

Gary M. Abramson*, Chairman of the Board, Partner, The Tower Companies, North Bethesda, MD

Thomas A. Gottschalk, Vice Chair of the Board, Executive Vice President, Law and Public Policy, and General Counsel, General Motors Corp., Detroit, MI

Stephanie M. Bennett-Smith, President Emerita, Centenary College, Hackettstown, NJ

David M. Carmen, President and CEO, Carmen Group Inc., Washington, DC

Edward R. Carr*, President (retired), CarrHomes, Inc., Falls Church, VA

Jack C. Cassell*, President and CEO, Visual Aids Electronics & Conference Systems, Inc., Germantown, MD

Gary D. Cohn*, President and Co-Chief Operating Officer, Goldman Sachs & Co., New York, NY

Pamela M. Deese*, Partner, Arent Fox PLLC, Washington, DC

Jerome King Del Pino, General Secretary, General Board of Higher Education and Ministry, United Methodist Church, Nashville, TN

David R. Drobis*, Chairman Emeritus, Ketchum Worldwide, Naples, FL

Gisela B. Huberman*, President, GBH Radio, Inc., Fisher Island, FL

Hani M.S. Farsi*, Managing Director and Chairman, Reservoir Management Services Ltd., London, England

C. Nicholas Keating, Jr.*, President and CEO, Network Equipment Technologies, Fremont, CA

Cornelius M. Kerwin*, Interim President, American University, Washington, DC

Margery Kraus*, President and CEO, APCO Worldwide, Washington, DC

Charles H. Lydecker*, Executive Vice President, Brown & Brown, Inc., Daytona Beach, FL

A. Robyn Mathias*, Principal (retired), Rolling Terrace Elementary School, Bethesda, MD

Regina L. Muehlhauser*, President (retired), Bank of America San Francisco, Pleasanton, CA

Matthew S. Pittinsky*, Chairman and Co-Founder, Blackboard, Inc., Washington, DC

Arthur J. Rothkopf, Senior Vice President and Counselor to the President, U.S. Chamber of Commerce, Washington, DC

Mark L. Schneider, Senior Vice President, International Crisis Group, Washington, DC

John R. Schol, Bishop, Baltimore-Washington Conference of The United Methodist Church, Washington, DC

Neal A. Sharma*, CEO, Digital Evolution Group, Overland Park, KS

Jeffrey A. Sine*, Vice Chairman and Global Head of Telecommunication and Technology, UBS Securities LLC, New York, NY

Posted in American University, El-Hibri Fuad, Fuad El-Hibri
Tags: , , , , , , ,

Bookmark and Share


Tags: , , , , , , ,

Reblog this post [with Zemanta]
Categories: American University, El-Hibri Fuad, Fuad El-Hibri, Fuad Elhibri Tags: , , , , , , ,

Fuad El-Hibri hires W. James Jackson, Ph.D.

June 21st, 2009 admin No comments
{{en|Difficult stamps with microscopes of the ...
Image via Wikipedia

Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions said, “After an extensive search including interviews with a variety of internal and external candidates, I am very pleased to appoint Dr. Jackson to this important post. Jim’s breadth and depth of experience and his intimate knowledge of our pipeline make him particularly suited to serve as Emergent’s chief scientific officer. I look forward to working closely with him in this new capacity and am confident his expertise will provide leadership to our development initiatives and add value to our company as a whole.”

ROCKVILLE, Md.–(Business Wire)– Emergent BioSolutions Inc. (NYSE: EBS) announced today that W. James Jackson, Ph.D., has been appointed chief scientific officer, effective immediately. Dr. Jackson will report directly to Fuad El-Hibri, chairman and chief executive officer.

As CSO, Dr. Jackson will lead the company’s scientific evaluation of new products and technology platforms and will be responsible for building and managing Emergent’s scientific advisory board. Additionally, Dr. Jackson will support the CEO in external communications by providing scientific expertise and perspective about the company’s technologies, platforms, and product candidates to government agencies and officials, investors, analysts and at scientific meetings.

“I am honored to be named chief scientific officer of Emergent BioSolutions. Because we are such a pioneering and growth-oriented company, I look forward to playing a leading role in the company’s new product acquisition efforts, and to applying my experience to help extend the company’s product portfolio in pursuit of our strategic goals,” said Dr. Jackson.

Dr. Jackson joined Emergent BioSolutions in 2003, as a result of Emergent’s acquisition of Antex Biologics Inc., where Dr. Jackson had been vice president of research and development. Since 2003, Dr. Jackson has served in several management capacities within the company including vice president, commercial product development and most recently as vice president, technical support. Dr. Jackson brings over 20 years of biopharmaceutical research and development experience to the company, including leading research efforts related to antigen identification and characterization, pre-clinical evaluation, and initial development of bacterial vaccines in the areas of respiratory, enteric, and sexually transmitted diseases. Among his accomplishments, Dr. Jackson has been issued 17 U.S. and foreign patents, obtained a number of state and federal research grants and has published frequently in various scientific journals. Dr. Jackson holds a Ph.D. in microbiology from the University of Georgia.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a profitable, multinational biopharmaceutical company dedicated to one simple mission — to protect life. We develop, manufacture and commercialize immunobiotics, consisting of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Our products target infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. Our marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. More information on the company is available at www.emergentbiosolutions.com.

Emergent BioSolutions Inc.
Investors:
Robert G. Burrows, 301-795-1877
Vice President, Investor Relations
BurrowsR@ebsi.com
or
Media:
Tracey Schmitt, 301-795-1800
Director, Corporate Communications
SchmittT@ebsi.com

Copyright Business Wire 2008

Posted in El-Hibri Fuad, Emergent BioSolutions, Emergent BioSolutions Inc, Fuad El-Hibri

Tags: , , , , , , , , , , , , , , ,

Reblog this post [with Zemanta]
Categories: Emergent BioSolutions, Fuad El-Hibri, W. James Jackson Tags: , , , , , , ,

Fuad El-Hibri on Anthrax Vaccine Contract

June 21st, 2009 admin No comments

“We strongly support this step by HHS, which potentially reduces development risk for our rPA vaccine candidate. We remain confident that we are well-positioned and competitive to receive any award granted by HHS for the development and procurement of the rPA vaccine. We look forward to continuing our long-standing relationship with the US Government as the proven and preeminent supplier of medical countermeasures to protect our nation,” said Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions.

Emergent BioSolutions Inc. (NYSE:EBS) announced that late on April 15th, HHS requested that each bidder in the competitive range for the rPA contract submit its product development plans to FDA for review in advance of an award. Emergent had already requested and is presently scheduling a meeting with the FDA as part of its pre-award activity. The Company intends to incorporate any FDA comments into its rPA development plan. Emergent will continue to move its rPA program forward to position the company to execute on the anticipated contract, once awarded.

As with any government solicitation of this size and scope, there are no assurances that HHS will not impose additional requirements, which may further extend contract negotiations.

This action has no impact on the company’s existing contracts with HHS to supply BioThrax®, the only FDA licensed anthrax vaccine, for the Strategic National Stockpile (SNS). This year Emergent is completing the delivery of 18.75 million doses of BioThrax for inclusion in the SNS. Also this year, following the completion of that delivery, Emergent will begin to supply HHS with an additional 14.5 million doses of BioThrax under a follow-on contract. The total value of these two procurement contracts with HHS for BioThrax exceeds $800 million.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax. Emergent’s development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia. Additional information may be found at http://www.emergentbiosolutions.com.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, including any potential future securities offering, and any other statements containing the words “believes,” “expects,” “anticipates,” “plans,” “estimates” and similar expressions, are forward-looking statements. There are a number of important factors that could cause the company’s actual results to differ materially from those indicated by such forward-looking statements, including the success of our clinical programs; our plans to expand our manufacturing facilities and capabilities; the rate and degree of market acceptance and clinical utility of our products; the timing of and our ability to obtain and maintain regulatory approvals for our other product candidates; our commercialization, marketing and manufacturing capabilities and strategy; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other factors identified in the company’s annual report on Form 10-K for the year ended December 31, 2008 and subsequent reports filed with the SEC. The company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Reblog this post [with Zemanta]
Categories: Anthrax Vaccine, El-Hibri Fuad, Fuad El-Hibri Tags: , , , , , , ,

Fuad El-Hibri and Emergent gets boost from FDA

June 21st, 2009 admin No comments
:Original raster version: :en::Image:Food and ...
Image via Wikipedia

“We are pleased that the FDA has approved the 4-year expiry dating of BioThrax as this extends the ability of the U.S. government to store our product in the nation’s Strategic National Stockpile,” said Fuad El-Hibri, chairman and CEO.

Emergent BioSolutions hit a jackpot of sorts when the Food and Drug Administration approved extending the shelf life of its anthrax vaccine from three to four years.

The milestone approval means that the vaccines that the Rockville biotech has already sold to the Department of Health and Human Services‘ Strategic National Stockpile are worth $30 million more than the original price. In a statement, Emergent said it plans to record that extra income in the current quarter.

Furthermore, the extended shelf life means that the value of the company’s contract for 14.5 million additional doses has increased to $405 million.

“This is a critically important product feature that we believe will increase the attractiveness of BioThrax to the U.S. government as it increases BioThrax’s life cycle value. We are continuing our efforts to further enhance the attributes of BioThrax, including research toward a further reduction in the vaccination schedule and an expanded label indication for post-exposure prophylaxis. We believe these enhancements, if approved, will advance the U.S. government’s preparedness efforts in response to anthrax as a potential weapon of bioterrorism.”

Emergent has supplied more than 33 million doses of BioThrax, the only FDA-approved anthrax vaccine, to the federal government, with more deliveries scheduled through the third quarter of 2011.

Also this week, Emergent sued privately held Protein Sciences Corp. of Meriden, Conn., which it planned to acquire last year, according to a filing with the Securities and Exchange Commission. In connection with the planned acquisition, Emergent made a $10 million loan to Protein Sciences, which used its assets as collateral. A May 31 deadline for repayment passed, prompting the suit, Emergent said.

Emergent also plans to proceed with its pending lawsuits against Protein Sciences and its management, including claims for breach of contract, fraud and unfair business practices.

Reblog this post [with Zemanta]
Categories: El-Hibri Fuad, FDA, Food and Drug Administration, Fuad El-Hibri, Fuad Elhibri Tags: , , , , , , ,

Anthrax Vaccine by Fuad El-Hibri

June 21st, 2009 admin No comments

An anthrax vaccine discovered and initially developed by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) has been acquired by a Maryland-based firm for advanced development that could lead to eventual licensure of the product by the Food and Drug Administration.

Fuad El-Hibri Next Generation Anthrax Vaccine

Jun 15
Comments

Fuad El-Hibri next generation anthrax vaccine

FOR IMMEDIATE RELEASE CONTACT: Caree Vander Linden
May 12, 2008 (301) 619-2285
Caree.Vander-Linden@amedd.army.mil

USAMRIID’s Next Generation Anthrax Vaccine Acquired for Advanced Development

According to company officials, Emergent BioSolutions Inc. has acquired the next generation anthrax vaccine, as well as the technology on which it is based. This vaccine candidate was patented by USAMRIID and previously licensed to a company called VaxGen, which had pursued advanced development since 2002 under a contract from the U.S. Department of Health and Human Services.The vaccine uses recombinant protective antigen, or rPA, a protein secreted by the anthrax bacterium, Bacillus anthracis. This protein induces the body’s immune system to produce antibodies against the bacteria’s toxins. In several nonhuman primate studies conducted at USAMRIID, rPA has demonstrated the ability to induce a high level of protection against inhalational anthrax—the type most likely to occur following a bioterrorist event.

“We believe this acquisition will facilitate the continued development of this promising anthrax vaccine candidate,” said Colonel George W. Korch, Jr., commander of USAMRIID. “We are excited about the future prospects for rPA as an effective medical countermeasure for the nation’s biodefense.”

Anthrax is caused by spores and most commonly occurs in wild and domestic mammals, although it has the potential to be used as a biological threat agent. Symptoms vary depending on the route of exposure; however, sore throat, mild fever, and muscle aches usually begin within 7 days of exposure. Severe breathing difficulty, shock, and meningitis can follow, and as the bacteria multiply in the lymph nodes, toxemia progresses and the potential for widespread tissue destruction and organ failure increases. Up to 90 percent of untreated cases of inhalational anthrax result in death. Obtaining an alternative for the currently licensed anthrax vaccine would provide the Department of Defense—and the nation—with additional options in protecting against this threat.

USAMRIID’s proprietary technology also has a number of potential manufacturing advantages, including the ability to express full-length soluble anthrax PA in a non-toxic, non

spore-forming strain of the anthrax bacterium. When full-length rPA is expressed in anthrax bacteria, it is secreted into the culture fluid, from which it can be isolated in a highly purified form. This material also has the potential to provide broader protection against anthrax.

“By acquiring this particular vaccine candidate, Emergent will be able to leverage over a decade of development work conducted at USAMRIID and 5 years of experience and advanced development work conducted by VaxGen, in order to continue the development of this vaccine through to licensure,” said Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions Inc.

USAMRIID, located at Fort Detrick, Maryland, is the lead medical research laboratory for the U.S. Department of Defense Biological Defense Research Program, and plays a key role in national defense and in infectious disease research. The Institute conducts basic and applied research on biological threats resulting in medical solutions (such as vaccines, drugs and diagnostics) to protect the warfighter. While USAMRIID’s primary mission is focused on the military, its research often has applications that benefit society as a whole. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command. For more information, visit www.usamriid.army.mil

###

Reblog this post [with Zemanta]
Categories: Anthrax Vaccine, BioThrax, Emergent BioSolutions, Fuad El-Hibri Tags: , , , , , , ,